Logo image of BIVI

BIOVIE INC (BIVI) Stock Fundamental Analysis

NASDAQ:BIVI - Nasdaq - US09074F4054 - Common Stock - Currency: USD

1.14  -0.05 (-4.2%)

After market: 1.1201 -0.02 (-1.75%)

Fundamental Rating

2

Taking everything into account, BIVI scores 2 out of 10 in our fundamental rating. BIVI was compared to 559 industry peers in the Biotechnology industry. While BIVI has a great health rating, there are worries on its profitability. BIVI is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BIVI has reported negative net income.
In the past year BIVI has reported a negative cash flow from operations.
In the past 5 years BIVI always reported negative net income.
In the past 5 years BIVI always reported negative operating cash flow.
BIVI Yearly Net Income VS EBIT VS OCF VS FCFBIVI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

BIVI has a worse Return On Assets (-78.52%) than 69.95% of its industry peers.
With a Return On Equity value of -88.75%, BIVI perfoms like the industry average, outperforming 49.02% of the companies in the same industry.
Industry RankSector Rank
ROA -78.52%
ROE -88.75%
ROIC N/A
ROA(3y)-134.59%
ROA(5y)-1013.33%
ROE(3y)-417.03%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BIVI Yearly ROA, ROE, ROICBIVI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BIVI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BIVI Yearly Profit, Operating, Gross MarginsBIVI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for BIVI has been reduced compared to 1 year ago.
Compared to 5 years ago, BIVI has more shares outstanding
The debt/assets ratio for BIVI has been reduced compared to a year ago.
BIVI Yearly Shares OutstandingBIVI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
BIVI Yearly Total Debt VS Total AssetsBIVI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

BIVI has an Altman-Z score of -16.83. This is a bad value and indicates that BIVI is not financially healthy and even has some risk of bankruptcy.
BIVI has a Altman-Z score of -16.83. This is amonst the worse of the industry: BIVI underperforms 81.75% of its industry peers.
BIVI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -16.83
ROIC/WACCN/A
WACCN/A
BIVI Yearly LT Debt VS Equity VS FCFBIVI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M -20M -30M -40M

2.3 Liquidity

A Current Ratio of 9.31 indicates that BIVI has no problem at all paying its short term obligations.
BIVI has a better Current ratio (9.31) than 75.85% of its industry peers.
A Quick Ratio of 9.31 indicates that BIVI has no problem at all paying its short term obligations.
With a decent Quick ratio value of 9.31, BIVI is doing good in the industry, outperforming 76.03% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.31
Quick Ratio 9.31
BIVI Yearly Current Assets VS Current LiabilitesBIVI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 55.37% over the past year.
EPS 1Y (TTM)55.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.47%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, BIVI will show a very strong growth in Earnings Per Share. The EPS will grow by 33.33% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y62.63%
EPS Next 2Y39.61%
EPS Next 3Y33.27%
EPS Next 5Y33.33%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BIVI Yearly Revenue VS EstimatesBIVI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2031 20M 40M 60M 80M 100M
BIVI Yearly EPS VS EstimatesBIVI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 20 -20 -40 -60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BIVI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BIVI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BIVI Price Earnings VS Forward Price EarningsBIVI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BIVI Per share dataBIVI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

BIVI's earnings are expected to grow with 33.27% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.61%
EPS Next 3Y33.27%

More info and screens

0

5. Dividend

5.1 Amount

BIVI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOVIE INC

NASDAQ:BIVI (6/13/2025, 8:00:02 PM)

After market: 1.1201 -0.02 (-1.75%)

1.14

-0.05 (-4.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)09-29 2025-09-29/amc
Inst Owners5.61%
Inst Owner Change31.9%
Ins Owners0.79%
Ins Owner Change0%
Market Cap21.16M
Analysts82.86
Price Target5.61 (392.11%)
Short Float %9.3%
Short Ratio3.12
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-84.18%
Min EPS beat(2)-181.86%
Max EPS beat(2)13.49%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)10%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.97
P/tB 1
EV/EBITDA N/A
EPS(TTM)-2.12
EYN/A
EPS(NY)-0.61
Fwd EYN/A
FCF(TTM)-0.94
FCFYN/A
OCF(TTM)-0.94
OCFYN/A
SpS0
BVpS1.18
TBVpS1.14
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -78.52%
ROE -88.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-134.59%
ROA(5y)-1013.33%
ROE(3y)-417.03%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.31
Quick Ratio 9.31
Altman-Z -16.83
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)55.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.47%
EPS Next Y62.63%
EPS Next 2Y39.61%
EPS Next 3Y33.27%
EPS Next 5Y33.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y50.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y49.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y49.99%
OCF growth 3YN/A
OCF growth 5YN/A